分類彙整：公司新聞

Watch This CEO Discuss A Potentially Ground-Breaking Vaccine for Alzheimers 繼續閱讀 →

Mei Mei Hu | Democratizing Brain Health | Global Summit 2018 | Singularity University 繼續閱讀 →

Tune in to watch sessions with a star-studded group of women, including Alphabet CFO Ruth Porat, U.S. Secretary of Transportation Elaine Chao, New York Stock Exchange president Stacey Cunningham, United Neuroscience CEO Mei Mei Hu, Land O’ Lakes CEO CEO Beth Ford, Estonia president Kersti Kaljulaid, NBC News host Megyn Kelly, Walmart International CEO Judith McKenna, and Bumble CEO Whitney Wolfe Herd. 繼續閱讀 →

聯亞集團與長庚大學建教合作-107學年度暑期實習成果競賽於107年9月3日圓滿順利完成，實習生們皆有非常優異的傑出表現！ 繼續閱讀 →

聯生藥預計8/29停止興櫃買賣，轉往海外掛牌！董事王長怡表示，根留台灣信念不變，將持續投資台灣，未來五年至少再投入數十億用於人才培育、新藥研發，且將再擴建至12條2,000公升生產線。 繼續閱讀 →

聯合生物製藥為長期發展策略，董事會決議終止櫃檯買賣(新聞稿&問答集) 繼續閱讀 →

聯生藥(6471)今日表示，開發中針對治療過敏症的創新抗IgE單株抗體UB-221研發成果備受肯定，榮獲2018年台北生技獎新創技術獎之「銅獎」。 繼續閱讀 →

聯生藥(6471)今日表示，已向台灣食品藥物管理署提交創新抗IgE 抗體新藥UB-221 之人體臨床一期試驗申請。此臨床一期試驗主要目的在於評估UB-221 對於使用蕁麻疹一線藥物但仍無顯著效果的慢性自發性蕁麻疹(Chronic Idiopathic Urticaria，CIU) 病患上的安全性與初步療效。 繼續閱讀 →

中國醫藥市場成長快速，已躍居全球第二大市場。然其抗體藥物產業才剛起步，2015及2016年的抗體藥物市場規模分別約78及104億元人民幣，隨著人口老齡化、人民經濟能力提升以及產業政策支持，預估2022年將達280～300億元人民幣，未來成長空間相當巨大。目前中國蛋白質／抗體藥物多是以生物仿製藥（Biosimilar） 為主，創新抗體藥將是一塊藍海，未來有很大的成長空間。 繼續閱讀 →

長庚大學生物科技產業博碩士學程於5月25日至聯合生物製藥蛋白質藥廠參訪及進行座談，活動內容除了介紹聯亞集團如何憑藉著遼闊的眼界及創新性思維，積極開創新局，來貫徹增進人類健康與生活品質的理想與使命外，也向學生說明新藥研發的流程與畢業後的就業出路；接著進行實驗室與產線參訪，最後由聯合生物製藥高階主管與長庚大學師生進行座談，使學生更加了解欲進入生技製藥產業界需具備的能力與心態。 繼續閱讀 →

DUBLIN, April 27, 2018 /PRNewswire/ — United Neuroscience, Ltd., today announced that company co-founder Lou Reese will present at the Fourth International Conference, Unite to Cure: A Global Health Care Initiative, held April 26-28, 2018, at the Aula Nuova del Sinodo in Vatican City. The conference, organized by the Pontifical Council for Culture and the Cura Foundation, brings together journalists, advocates and thought leaders to discuss the impact of scientific innovation in medicine on culture and society. 繼續閱讀 →

美國UBI集團暨聯生藥(6471)與聯亞藥(6562)董事長王長怡博士受邀於25日在揚州月畔灣酒店由揚州國家高新技術產業開發區舉辦的「2018揚州生物醫藥論壇」中給予專題演講。 繼續閱讀 →

Candidates Generated with United Neuroscience Endobody Technology Will be Tested at the Center for Alzheimer’s and Neurodegenerative Diseases 繼續閱讀 →

DUBLIN, March 22, 2018 /PRNewswire/ — United Neuroscience, Ltd., (UNS), today announced that it has entered a research collaboration agreement with the Ronald Melki laboratory at the French National Center for Scientific Research (CNRS) to investigate applications of the United Neuroscience Endobody technology platform in targeting pathogenic forms of alpha-synuclein protein. Under the agreement, United Neuroscience will contribute novel candidates targeting specific protein aggregates using the Endobody technology platform. Researchers in the CNRS laboratory will provide expertise in characterization of these candidates for key properties for their potential in generating therapeutics for Parkinson’s disease and other synucleinopathies. 繼續閱讀 →

LOS ANGELES, March 15, 2018 /PRNewswire-USNewswire/ — The Society for Brain Mapping and Therapeutics (SBMT) officially announced today they will hold their 15th Annual World Congress at the Millennium Biltmore Hotel in DTLA from April 13-15, 2018. The event will include more than 400 scientists, engineers, physicians and surgeons where they will discuss pioneering technologies, policies and science advances in the fields including: multimodality imaging, nanoneurosurgery, nanobioelectronics, neurophotonics, cellular therapeutics (stem cell and neuro-immunotherapey), supercomputing, robotics (brain computer interface), neural transplantation and repair (double hand transplants), neuroengineering, Artificial Intelligence (AI), augmented reality and virtual reality in clinical neuroscience as well as computational and predictive modeling. 繼續閱讀 →